BACKGROUND: Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that has demonstrated superior efficacy over interferon (IFN)-alpha in a phase III trial in first-line, metastatic renal cell carcinoma (RCC). Herein, we report the results of a phase I dose-finding study of sunitinib in combination with IFN-alpha as first-line treatment in patients with metastatic RCC. PATIENTS AND METHODS: Treatment-naive patients with clear-cell metastatic RCC received sunitinib at a starting dose of 50 mg or 37.5 mg orally once daily in 6-week cycles (schedule 4/2) plus IFN-alpha at a starting dose of 3 MU subcutaneously 3 times a week, with weekly intrapatient dose escalation to a maximum of 9 MU as tolerated. Patients who did not tolerate either drug received lower doses of either or had dose interruptions. RESULTS: Twenty-five patients were enrolled; their median age was 64 years (range, 45-77 years). All patients experienced grade 3/4 treatment-emergent adverse events; the most common were neutropenia, fatigue, and thrombocytopenia. After a median of 4 cycles (range, 1-9 cycles), 3 patients (12%) had a partial response, and 20 (80%) had stable disease. CONCLUSION: Although reduced starting doses were tolerated (37.5 mg for sunitinib and 3 MU for IFN-alpha), even these lower doses might not be well tolerated for long-term treatment of patients with metastatic RCC. Based on historical data, sunitinib on schedule 4/2 appears to be more effective as single-agent therapy. Further study of sunitinib plus IFN-alpha on this schedule is not being pursued in RCC.
BACKGROUND:Sunitinib malate is an oral, multitargeted tyrosine kinase inhibitor that has demonstrated superior efficacy over interferon (IFN)-alpha in a phase III trial in first-line, metastatic renal cell carcinoma (RCC). Herein, we report the results of a phase I dose-finding study of sunitinib in combination with IFN-alpha as first-line treatment in patients with metastatic RCC. PATIENTS AND METHODS: Treatment-naive patients with clear-cell metastatic RCC received sunitinib at a starting dose of 50 mg or 37.5 mg orally once daily in 6-week cycles (schedule 4/2) plus IFN-alpha at a starting dose of 3 MU subcutaneously 3 times a week, with weekly intrapatient dose escalation to a maximum of 9 MU as tolerated. Patients who did not tolerate either drug received lower doses of either or had dose interruptions. RESULTS: Twenty-five patients were enrolled; their median age was 64 years (range, 45-77 years). All patients experienced grade 3/4 treatment-emergent adverse events; the most common were neutropenia, fatigue, and thrombocytopenia. After a median of 4 cycles (range, 1-9 cycles), 3 patients (12%) had a partial response, and 20 (80%) had stable disease. CONCLUSION: Although reduced starting doses were tolerated (37.5 mg for sunitinib and 3 MU for IFN-alpha), even these lower doses might not be well tolerated for long-term treatment of patients with metastatic RCC. Based on historical data, sunitinib on schedule 4/2 appears to be more effective as single-agent therapy. Further study of sunitinib plus IFN-alpha on this schedule is not being pursued in RCC.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: R J Motzer; B A Murphy; J Bacik; L H Schwartz; D M Nanus; T Mariani; P Loehrer; G Wilding; D L Fairclough; D Cella; M Mazumdar Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: Robert J Motzer; Gary R Hudes; Brendan D Curti; David F McDermott; Bernard J Escudier; Sylvie Negrier; Brigitte Duclos; Laurence Moore; Timothy O'Toole; Joseph P Boni; Janice P Dutcher Journal: J Clin Oncol Date: 2007-09-01 Impact factor: 44.544
Authors: Zofia von Marschall; Arne Scholz; Thorsten Cramer; Georgia Schäfer; Michael Schirner; Kjell Oberg; Bertram Wiedenmann; Michael Höcker; Stefan Rosewicz Journal: J Natl Cancer Inst Date: 2003-03-19 Impact factor: 13.506
Authors: Jared A Gollob; W Kimryn Rathmell; Tina M Richmond; Christine B Marino; Elizabeth K Miller; Gayle Grigson; Catharine Watkins; Lin Gu; Bercedis L Peterson; John J Wright Journal: J Clin Oncol Date: 2007-08-01 Impact factor: 44.544
Authors: Robert J Motzer; M Dror Michaelson; Jonathan Rosenberg; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; George Wilding Journal: J Urol Date: 2007-09-17 Impact factor: 7.450
Authors: Napoleon Santos; Justin B Wenger; Pamela Havre; Yanxia Liu; Roi Dagan; Iman Imanirad; Alison M Ivey; Robert A Zlotecki; Chester B Algood; Scott M Gilbert; Carmen J Allegra; Paul Okunieff; Johannes Vieweg; Nam H Dang; Hendrik Luesch; Long H Dang Journal: Oncology Date: 2011-11-12 Impact factor: 2.935
Authors: W Marston Linehan; Gennady Bratslavsky; Peter A Pinto; Laura S Schmidt; Len Neckers; Donald P Bottaro; Ramaprasad Srinivasan Journal: Annu Rev Med Date: 2010 Impact factor: 13.739
Authors: Andreas Varkaris; Wenxin Xu; Roger B Davis; Brian Healy; David F McDermott Journal: Clin Genitourin Cancer Date: 2019-12-05 Impact factor: 2.872